Bristol Myers Squibb hasn’t splashed out as much money as some of its peers in the fast-growing field of antibody drug conjugate (ADC) cancer therapies, but the pharmaceutical giant just struck a deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results